Driving Sterile Innovation At Scale

PCI Pharma Services is rapidly expanding its capabilities in advanced drug delivery through strategic investments and acquisitions. The recent acquisition of Ajinomoto Althea in San Diego significantly boosts PCI’s sterile fill/finish offerings in North America, adding new technologies and expertise for complex biologics like mRNA and antibody-drug conjugates (ADCs).

Coupled with new high-speed prefilled syringe (PFS) technology in Europe and a major $100M investment at its Bedford, NH facility, PCI is building a global network that offers seamless, end-to-end solutions from early-stage development to large-scale commercial production. This integrated approach, which includes new pharmaceutical development centers and a focus on drug-device combination therapies, is designed to simplify the supply chain and accelerate the delivery of life-changing treatments to patients worldwide.